Media coverage about Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) has been trending somewhat positive on Tuesday, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novelion Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.343766443354 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Several equities analysts recently weighed in on NVLN shares. Zacks Investment Research upgraded Novelion Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 11th. Royal Bank of Canada reiterated a “hold” rating and set a $7.00 target price (down from $8.00) on shares of Novelion Therapeutics in a research report on Friday. Finally, ValuEngine downgraded Novelion Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st.
Novelion Therapeutics (NASDAQ NVLN) traded down $0.15 during midday trading on Tuesday, reaching $4.16. The company had a trading volume of 2,709 shares, compared to its average volume of 47,199. Novelion Therapeutics has a 1 year low of $3.08 and a 1 year high of $11.00. The stock has a market capitalization of $84.91, a P/E ratio of -0.62 and a beta of 0.84. The company has a debt-to-equity ratio of 6.53, a current ratio of 1.45 and a quick ratio of 1.28.
About Novelion Therapeutics
Novelion Therapeutics Inc, formerly QLT Inc, is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.
Receive News & Ratings for Novelion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.